{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/XSTO/SE0020353928",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Moberg Pharma AB (Nasdaq Stockholm: SE0020353928) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Moberg Pharma AB, listed on Nasdaq Stockholm under ticker SE0020353928, with ISIN SE0020353928 and LEI 549300XFXK7DVGDRP410. Its security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 38 filings on 18 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 14 days, and the latest filing is 3 days before the record date of 2026-11-06. The latest filing is dated 2026-11-03 and is of type Inside information. Nasdaq Stockholm carries a median of 30.0 filings, a median cadence gap of 9.5 days and a median latency of 7.0 days across 398 issuers. The sector median for SE is not on the record.\n\n## Auditor\n\nThe auditor of record is not on the record, and neither is its location. The market's record does not carry auditor changes for this register.\n\n## Events and halts\n\nThe record does not carry listing, delisting, name change, domicile change or segment move lines for this register, as the index holds no lifecycle type map for SE. The halt flag is listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable under acm-68000/se/mifid-ii-product-governance/r1, because the chapter as of 2026-11-04 carries no client categories. The outcome therefore cannot name its client category.\n\n## Coverage\n\nOne research house is named on the issuer's own investor-relations page: Redeye.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/XSTO/SE0020353928 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://www.mobergpharma.se/sv/investerare/analytiker (coverage)\n- https://mcp.se-cm-kg.ai/record/XSTO/SE0020353928 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/XSTO/SE0020353928",
  "coverage": {
   "count": 1,
   "houses": [
    {
     "analyst": "Jessica Grunewald",
     "house": "Redeye",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://www.mobergpharma.se/sv/investerare/analytiker",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://www.mobergpharma.se/sv/investerare/analytiker",
     "result": "read: 1 of 2 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 398,
     "median_cadence_gap_days": 9.5,
     "median_filings": 30,
     "median_latency_days": 7,
     "name": "Nasdaq Stockholm"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Changes board/management/auditors": 2,
    "Decisions of general meeting": 2,
    "Financial Statement Release": 2,
    "Inside information": 10,
    "Interim report (Q1 and Q3)": 6,
    "Investor News": 6,
    "Notice to general meeting": 2,
    "Other information disclosed according to the rules of the Exchange": 6,
    "Total number of voting rights and capital": 2
   },
   "cadence_median_gap_days": 14,
   "filing_days": 18,
   "filings": 38,
   "latency_days": 3,
   "latest": [
    {
     "category": "Inside information",
     "date": "2026-11-03",
     "source": "https://view.news.eu.nasdaq.com/view?id=bc855bf7c77df0b09cbcefcb72539cb55&lang=en&src=listed",
     "title": "Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015",
     "type": "Inside information"
    },
    {
     "category": "Inside information",
     "date": "2026-11-03",
     "source": "https://view.news.eu.nasdaq.com/view?id=b6436e70f9c968cbd68947a57e37012ac&lang=sv&src=listed",
     "title": "Moberg Pharma beviljas amerikanskt patent avseende förbättrad dosering av MOB-015",
     "type": "Inside information"
    },
    {
     "category": "Other information disclosed according to the rules of the Exchange",
     "date": "2026-10-20",
     "source": "https://view.news.eu.nasdaq.com/view?id=be09fa0fd9a259abe247eaba6a0f51336&lang=sv&src=listed",
     "title": "Moberg Pharmas valberedning utsedd",
     "type": "Other information disclosed according to the rules of the Exchange"
    },
    {
     "category": "Other information disclosed according to the rules of the Exchange",
     "date": "2026-10-20",
     "source": "https://view.news.eu.nasdaq.com/view?id=b01de97d48321f55be2a887ea3732baf9&lang=en&src=listed",
     "title": "Moberg Pharma's Nomination Committee appointed",
     "type": "Other information disclosed according to the rules of the Exchange"
    },
    {
     "category": "Investor News",
     "date": "2026-10-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=b83b8b73f089f64d8cd1a803b5402924a&lang=en&src=listed",
     "title": "New analyses on terbinafine susceptibility and MOB-015 published in Journal of Fungi",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-11-03",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0020353928",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Stockholm"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0020353928"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0020353928)",
    "state": "sourced",
    "value": "549300XFXK7DVGDRP410"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Moberg Pharma AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0020353928"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:b833e1e320bded34d6425b1336a84636d3894675a7a9bcd9c04ac2af2b52b9e6",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/XSTO/SE0020353928",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:b833e1e320bded34d6425b1336a84636d3894675a7a9bcd9c04ac2af2b52b9e6",
 "path": "/se/XSTO/SE0020353928",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Moberg Pharma AB, listed on Nasdaq Stockholm under ticker SE0020353928, with ISIN SE0020353928 and LEI 549300XFXK7DVGDRP410. Its security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 38 filings on 18 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 14 days, and the latest filing is 3 days before the record date of 2026-11-06. The latest filing is dated 2026-11-03 and is of type Inside information. Nasdaq Stockholm carries a median of 30.0 filings, a median cadence gap of 9.5 days and a median latency of 7.0 days across 398 issuers. The sector median for SE is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, and neither is its location. The market's record does not carry auditor changes for this register.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record does not carry listing, delisting, name change, domicile change or segment move lines for this register, as the index holds no lifecycle type map for SE. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable under acm-68000/se/mifid-ii-product-governance/r1, because the chapter as of 2026-11-04 carries no client categories. The outcome therefore cannot name its client category.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "One research house is named on the issuer's own investor-relations page: Redeye.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, and the market's earliest sealed date and the live record start date are not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0020353928"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://www.mobergpharma.se/sv/investerare/analytiker"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/XSTO/SE0020353928"
  }
 ],
 "title": "Moberg Pharma AB (SE0020353928) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}